Durable response to nivolumab rechallenge in a patient with metastatic clear cell renal cell carcinoma

Durable response to nivolumab rechallenge in a patient with metastatic clear cell renal cell carcinoma

Introduction While immune checkpoint inhibitors represent the mainstream treatment for metastatic renal cell carcinoma, a standardized approach following immune checkpoint inhibitors remains unclear. We report a case of metastatic renal cell carcinoma treated with nivolumab rechallenge. Case present...

Full description

Bibliographic Details
Main Authors: Motohiro Fujiwara, Wataru Shimada, Minato Yokoyama, Anri Koyanagi, Hiroshi Shintaku, Shohei Fukuda, Yuma Waseda, Hajime Tanaka, Soichiro Yoshida, Yasuhisa Fujii
Format: Article
Language:English
Published: Wiley 2024-07-01
Series:IJU Case Reports
Subjects:
clear cell renal cell carcinoma
immune checkpoint inhibitors
nivolumab
nivolumab rechallenge
Online Access:https://doi.org/10.1002/iju5.12727

Internet

https://doi.org/10.1002/iju5.12727

Similar Items